title: Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.
abstract: Insulin glargine 300 U/mL (Toujeo(®)) is a long-acting basal insulin analogue approved for the treatment of diabetes mellitus. Insulin glargine 300 U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus(®)), with a duration of glucose-lowering activity exceeding 24 h. In several 6-month phase III trials, insulin glargine 300 U/mL achieved comparable glycaemic control to that seen with insulin glargine 100 U/mL in patients with type 1 or type 2 diabetes, albeit with consistently higher daily basal insulin requirements. These improvements in glycaemic control were maintained during longer-term (12 months) treatment. Insulin glargine 300 U/mL was generally associated with a lower risk of nocturnal hypoglycaemia than insulin glargine 100 U/mL in insulin-experienced patients with type 2 diabetes, while the risk of nocturnal hypoglycaemia did not significantly differ between treatment groups in insulin-naïve patients with type 2 diabetes or in patients with type 1 diabetes. To conclude, once-daily subcutaneous insulin glargine 300 U/mL is an effective and generally well tolerated basal insulin therapy option for patients with type 1 or type 2 diabetes.
authors.affiliation: Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
authors.forename: Hannah A
authors.initials: HA
authors.lastname: Blair
authors.affiliation: Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Keating
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D017326:Clinical Trials, Phase III as Topic; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007232:Infant, Newborn, Diseases / Q000097:blood / Q000188:drug therapy*; D007279:Injections, Subcutaneous; D000069036:Insulin Glargine / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000069036:Insulin Glargine
references.citation: Diabetes Obes Metab. 2015 Apr;17(4):386-94
references.pmid: 25641260
references.citation: Can J Diabetes. 2015 Aug;39(4):335-43
references.pmid: 26233724
references.citation: Diabetes Care. 2015 Jan;38(1):140-9
references.pmid: 25538310
references.citation: Diabetes Care. 2015 Apr;38(4):637-43
references.pmid: 25150159
references.citation: Diabetes Obes Metab. 2015 Sep;17(9):835-42
references.pmid: 25846721
references.citation: Diabetes Care. 2012 Jun;35(6):1364-79
references.pmid: 22517736
references.citation: Drugs. 2003;63(16):1743-78
references.pmid: 12904090
references.citation: Diabetes Obes Metab. 2014 Sep;16(9):873-6
references.pmid: 24571126
references.citation: Diabetes Obes Metab. 2015 Sep;17(9):859-67
references.pmid: 25929311
references.citation: Diabetes Metab Res Rev. 2014 Feb;30(2):104-19
references.pmid: 24026961
references.citation: Clin Diabetes. 2015 Apr;33(2):97-111
references.pmid: 25897193
references.citation: Diabetes Care. 2015 Dec;38(12):2217-25
references.pmid: 26084341
references.citation: Drugs. 2013 May;73(6):575-93
references.pmid: 23620200
references.citation: Diabetes Obes Metab. 2015 Mar;17(3):254-60
references.pmid: 25425297
references.citation: Diabetes Obes Metab. 2015 Mar;17(3):261-7
references.pmid: 25425394
references.citation: Diabetes Ther. 2015 Jun;6(2):143-52
references.pmid: 26055218
references.citation: Diabetes Care. 2014 Dec;37(12):3235-43
references.pmid: 25193531
references.citation: Diabetes Obes Metab. 2008 Nov;10(11):1105-13
references.pmid: 18355326
references.citation: Expert Opin Biol Ther. 2014 Jun;14(6):799-808
references.pmid: 24673155
references.citation: Diabetes Obes Metab. 2015 Dec;17(12):1142-9
references.pmid: 26172084
references.citation: J Diabetes Sci Technol. 2015 Jul;9(4):936-8
references.pmid: 26002837
references.citation: Diabetes Care. 2014 Oct;37(10):2755-62
references.pmid: 25078900